The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (pts) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 Results
Authors
Halperin, D. M.Johnson, M. L.
Chan, J. A.
Hart, L. L.
Cook, Natalie
Patel, V. M.
Schlecter, B. L.
Cave, J.
Dowlati, A.
Blaszkowsky, L. S.
Meyer, T.
Eads, J. R.
Culp, D.
Kriksciukaite, K.
Mei, L.
Bilodeau, M.
Bloss, J.
Kulke, M. H.
Affiliation
The University of Texas MD Anderson Cancer Center, Houston, TXIssue Date
2022